Form 8-K - Current report:
SEC Accession No. 0001804591-25-000005
Filing Date
2025-01-28
Accepted
2025-01-28 17:18:58
Documents
14
Period of Report
2025-01-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K me-20250128.htm   iXBRL 8-K 25506
2 EX-99.1 me-20250128x8kxexx991.htm EX-99.1 217789
  Complete submission text file 0001804591-25-000005.txt   385137

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT me-20250128.xsd EX-101.SCH 1776
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT me-20250128_lab.xml EX-101.LAB 21633
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT me-20250128_pre.xml EX-101.PRE 12508
16 EXTRACTED XBRL INSTANCE DOCUMENT me-20250128_htm.xml XML 2699
Mailing Address 223 N. MATHILDA AVE. SUNNYVALE CA 94086
Business Address 223 N. MATHILDA AVE. SUNNYVALE CA 94086 (650) 938-6300
23andMe Holding Co. (Filer) CIK: 0001804591 (see all company filings)

IRS No.: 871240344 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-39587 | Film No.: 25565767
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)